General protective or antinoxious agents (A61P39)

A   Human necessities(312083)
A61P39                 General protective or antinoxious agents(420)
A61P39/02 - Antidotes(57)
A61P39/04 - Chelating agents(13)
ethod for increase of organism resistance to combined toxic action of nanoparticles of copper, zinc and lead oxides // 2642674
FIELD: medicine.SUBSTANCE: method for reduction of the adverse effects of combined effects of copper (CuO), zinc (ZnO) and lead (PbO) oxides nanoparticles on organism in risk groups covering individuals exposed to such effects under production conditions. Method includes prescription of a complex of biologically active drugs: glutaminic acid, glycine, N-acetylcysteine, pectin enterosorbent, fish oil preparation rich in unesterified omega-3 fatty acids, Vitamins A, C, D3, E, selenium, iron and iodized preparations. This complex is taken by repeated courses 1-2 times a year for 4-6 weeks daily at doses providing daily intake of 300 mg of glycine, 600 mg of cysteine, 4 g of glutaminic acid, 25 ml of fish oil with 12-15% content of polyunsaturated omega-3 fatty acids, 4-5 grams of pectin, as well as selenium, iron, iodine and these vitamins in doses that provide the normal physiological needs of the organism.EFFECT: reduction of all three metals in the blood, improved elimination function of the liver and kidneys, reduced integral signs of chronic intoxication, including signs of neurotoxicity, and genotoxic combined action of copper, zinc and lead oxides nanoparticles on the body.6 tbl

Flavonoid-based composition for pharmaceutical, dietary or cosmetic application with enhanced antioxidant action // 2640915
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition possessing antioxidant activity against free radicals, containing: a) extract of seeds or seeds and leaves of Vitis vinifera, including a combination of quercetin and catechin flavonoids content at a molar ratio in the range from 6:1 to 3:1, or a') extract of seeds or seeds and leaves of Vitis vinifera, including a combination of quercetin and catechin flavonoids content at a molar ratio in the range from 7:1 to 4:1, or a") blend of Vitis vinifera extracts of a) and a'), or a'") a mixture of catechin and quercetin at a molar ratio in the range from 7:1 to 3:1, along with b) Olea europaea L. olive leaves extract containing hydroxytyrosol in an amount ranging from 1% to 30% of the extract mass, or b') hydroxytyrosol in an amount equal to the one contained in the extract (b), wherein the a'), or a"), or a"') and b), or b') ration is in the range between 6:1 to 6:3. Cosmetic application of the composition to provide antioxidant activity against free radicals. Composition application as a food dietary supplement to provide antioxidant activity against free radicals.EFFECT: compositions described above have a pronounced synergistic antioxidant activity.22 cl, 2 dwg, 8 ex

Geroprotector for model animals // 2639500
FIELD: pharmacology.SUBSTANCE: invention relates to application of 5-aminoimidazole-4-carboxamidiborofuranoside (AICAR) as a geroprotector in a nutrient medium for model animals. In case of nematodes, the geroprotective effect of AICAR is achieved in concentrations of 0.05 mM and 0.1 mM. In case of drosophila flies, the geroprotective effect of AICAR is achieved in concentrations of 0.5 mM and 1.0 mM.EFFECT: increased life expectancy of model animals.3 cl, 5 dwg, 3 ex
ethod for prevention of neurological status and muscular tonus violations in acute radiation disease in experiment // 2638270
FIELD: medicine.SUBSTANCE: to prevent psychoneurological disturbances in an animal experiment after single uneven proton irradiation at doses capable of causing acute radiation disease, Semax preparation 0.1% nasal drops is administered intranasally. Semax is injected 1 drop into each nostril three times a day from 1 to 7 days after exposure to radiation.EFFECT: method allows to maintain a normal level of the orienting-research reaction, emotional status, the relationship between the excitation and inhibition processes of the central nervous system and muscle tone, disturbed by proton irradiation.2 ex, 1 tbl

Pharmaceutical possessing hypolidemic, hepatoprotective and antioxidant action // 2636817
FIELD: pharmacology.SUBSTANCE: pharmaceutical contains a powder of medicinal and food plants, as well as calcium gluconate and camphor with a certain ratio of components. This agent can be used both in the form of a powder and in the form of capsules. Pharmaceutical and capsules based on it can be used in the treatment and prevention of atherosclerosis, coronary heart disease (CHD), hyperpiesis, diabetes, obesity, varying degrees of lipid and carbohydrate metabolism, as well as in geriatric practice.EFFECT: increased efficiency of the pharmaceutical use.16 tbl, 1 dwg, 2 ex
Benzylpenicillin sodium salt as means of preventive measures and early medical maintenance of acute sulphur mustard damage // 2635504
FIELD: pharmacology.SUBSTANCE: it is proposed to use the official medicinal agent - benzylpenicillin sodium salt. In comparison with the agent-prototype (sodium thiosulfate) the benzylpenicillin sodium salt has the reciprocal protective efficiency in regard to the sulphur mustard resorptive effect, but at the same time, its application is in 20 doses lower and 5-times lower in volume with more optimal administration route (subcutaneous administration). That is illustrative of agent's advantage, when the mass use is necessary for prophylactic purposes and in the early treatment.EFFECT: effective preventive measures and early medical maintenance of acute sulphur mustard damage.3 tbl, 3 ex
Bicillin-1 as means for prevention and early therapy of acute injuries caused by sulphur mustard // 2635476
FIELD: medicine.SUBSTANCE: application of the official medicinal product of penicillin - bicillin-1 as means for prevention and early therapy of acute lesions caused by the resorptive action of sulfur mustard is proposed.EFFECT: compared to the prototype, bicillin-1 has equal protective efficiency with respect to the resorptive action of sulfur mustard, but it is used in 20 times lesser dose and 5 times smaller volume with a more optimal way of administration, which indicates its advantage in case of mass use in preventive and early treatment.3 tbl, 3 ex
Complex compound of 5-hydroxy-1,3,6-trimethyluracyl with ambient acid, antidite activity and method of its production // 2634731
FIELD: chemistry.SUBSTANCE: compound is produced by mixing succinic acid and 5-hydroxy-1,3,6-trimethyluracil in an equimolar amount in an organic solvent by heating the reaction mixture. Preferably, the process is carried out at a temperature of up to 40°C followed by cooling and filtration of the precipitated crystals. The compound is produced in 90% yield.EFFECT: compound has antidote activity under conditions of exposure to toxic doses of poison - methaemoglobin-forming agent.4 cl, 5 tbl, 3 ex
Complex connection of 5-hydroxy-3,6-dimethyluracyl with succinic acid exhibiting membrane-stabilizing activity and method of its production // 2631238
FIELD: chemistry.SUBSTANCE: complex compound is produced by mixing equimolar amounts of 5-hydroxy-3,6-dimethyluracil with succinic acid in an organic solvent, followed by heating the reaction mixture for 1 hour at 70°C, cooling the reaction mixture and filtering the precipitated crystals. .EFFECT: having membrane-stabilizing and anti-radical activity, reduced toxicity in comparison with the known compounds of identical purpose.2 cl, 3 tbl, 4 ex
Composition with antioxidant activity and its application // 2630579
FIELD: pharmacology.SUBSTANCE: composition with antioxidant activity, containing a gel from aloe vera leaves; grapes juice; green tea extract; vitamin mixture containing vitamin B1, vitamin B9, vitamin B12 and vitamin E; chlorophyll; coenzyme Q10; choline; selenium and a wheat unit extract containing 10% of resveratrol taken in a certain amount.EFFECT: composition provides high antioxidant activity.10 cl, 1 tbl, 3 ex
Pharmaceutical "biobardin" pills with antioxidant action obtained based on post-alcohol grain distillery dreg // 2630466
FIELD: pharmacology.SUBSTANCE: invention relates to a method for preparation of an antioxidant drug in the form of pills based on biologically active compounds (BAC) of post-alcohol grain distilled dreg. First, effective antioxidant drug (pharmaceutical substance) "Biobaridin" is obtained from liquid and solid phases of post-alcohol grain distilled dreg by a known mehod (Pat. RF No. 2404766) in a powder form. The substance is then ground, powder fraction passed through a sieve with a hole diameter of 1.0 mm (sieve No. 10) and not passed through a sieve with a hole diameter of 0.5 mm (sieve No. 05) is selected, i.e. coarse powder with a particle size of 0.5-1.0 mm is selected. The selected substance fraction is mixed for 5 minutes with calcium hydrogen phosphate (filler), granulated with 10% alcohol solution of collidon-25 (binder), dried in a fluidized bed at a temperature of 40°C for 30 minutes (up to the residual granulate moisture content of 2.8%), dry granulate is passed through a sieve with a hole diameter of 1.5 mm (sieve No. 15), "powdered" with calcium stearate (lubricant) and pressed into "Biobardin" pills. The composition of one "Biobardin" pill weighing 0.21 g: "Biobardin" substance 0.16 g, calcium hydrophosphate 0.04 g, collidon-25 0.009 g (or 0.09 g of 10% collidon-25 alcohol solution), calcium stearate 0.001 g.EFFECT: development of the composition and technology of antioxidant pills based on biologically active compounds isolated from distilled dreg, possessing optimal parameters for pharmaceutical use, long shelf life.2 cl, 1 ex, 11 tbl
Bicillin-3 as means for prevention and early therapy of acute sulphur mustard injuries // 2629602
FIELD: pharmacology.SUBSTANCE: for prevention and early therapy of acute injuries with sulfur mustard, a known drug is proposed to be used, which is a penicillin preparation bicillin-3.EFFECT: protective effectiveness in terms of resorptive action of sulfur mustard, bicillin-3 is not inferior to the prototype, but it is used at a 20 times lesser dose and 5 times smaller volume with a more optimal route of administration, which indicates its advantage when necessary for mass use for prevention and early treatment.3 tbl, 3 ex
Polybacterial drug with advantages for health: with antioxidant effect, decreased cholesterol concentration, anti-inflammatory and immuno-modulating effect, and release of bioactive peptides inhibiting angiotensin-converting enzyme // 2627651
FIELD: biotechnology.SUBSTANCE: group of inventions refers to polybacterial probiotic drug including new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No. 8722 and Lactobacillus helveticus A1, NBIMCC No. 8721, which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity. The group of inventions also refers to the use of drug as a probiotic agent, as well as an agent which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity.EFFECT: food additives, food and functional products, pharmaceutical preparations that include this drug, have a beneficial effect on the health of people and animals.9 cl, 8 dwg, 15 tbl
edical adsorbent and method for its obtaining // 2627464
FIELD: medicine.SUBSTANCE: medical adsorbent contains activated carbon in the form of spherical pellets, obtained by carbonizing and activation of regenerated cellulose in a spherical shape, and having average pore diameter of 1.5 to 2.2 nm, specific BET surface area of 700 to 3000 m2/g, average particle size of 115 to 1002 mcm, oxide content of 0.05 meq/g or more on the surface, and packing density of 0.4 to 0.8 g/ml. Method for adsorbent production comprises the steps of: spherical viscose conversion into regenerated spherical cellulose in an acid precipitation bath, and carbonizing of the resulting regenerated spherical cellulose at a temperature of 300°C to 700°C under a nitrogen atmosphere, and then steam activation at a temperature of 750°C to 1000°C, acid cleaning and heat treatment at a temperature of 500°C to 800°C. It can be used as a therapeutic or prophylactic agent for kidney disease or liver disease for oral administration.EFFECT: adsorbent has low dosage and excellent adsorption capacity and selective adsorption of toxins, it can shorten the activation time, it is economical and environmentally friendly.6 cl, 6 ex, 3 tbl
2-[6-methyl-4-(tietane-3-yloxy)pyrimidine-2-ylthio] acetic acid methylidenhydrazide with antioxidant activity // 2626651
FIELD: pharmacology.SUBSTANCE: invention relates to a new compound of -(5-bromo-2-hydroxyphenyl)methylidenehydrazide of 2-[6-methyl-4-(thietane-3-yloxy)pyrimidin-2-ylthio]acetic acid of formula I .EFFECT: compound has antioxidant activity and stimulating protective activity of phagocytes.3 cl, 4 tbl, 4 ex
Therapeutic application of krill oil // 2625760
FIELD: medicine.SUBSTANCE: proposed: method for endotoxemia treatment by parenteral administration of a krill oil composition containing phospholipids derived from krill, in an oil-in-water emulsion for injection, wherein triglycerides comprise at least 60% of omega-3 fatty acids based on the total weight of fish oil triglyceride fatty acids; application of the said composition for the same purpose; method for high-lipophilic drugs excessive doses toxicity neutralisation or drugs harmful effects reduction, comprising parenteral administering of the said composition; use of krill oil containing phospholipids derived from krill as an emulsifier in an oil-in-water emulsion in the composition for injection, and its use for endotoxemia treatment during sepsis.EFFECT: stability and safety of claimed compositions for intravenous administration.5 cl, 9 tbl
Pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol, method for its production and applications for cardiovascular diseases treatment // 2625039
FIELD: pharmacology.SUBSTANCE: pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol for cardiovascular diseases treatment contains a therapeutically effective amount of O-(4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]hept-exo-2-yl)benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1,4)-α-D-glucan (Dibornol-HEC) as an active ingredient. Sodium chloride, Tween 80, ascorbic acid, water for injection or saline in the amounts indicated in the claims are used as auxiliary components. In the method for pharmaceutical injection form preparation, the Dibornol-HEC substance is added to an aqueous solution of Tween 80 surfactant and mixed until the substance is dissolved completely and a clear solution is obtained, the water is distilled off under reduced pressure, ascorbic acid, sodium chloride, saline (water for injection) are added to the dry residue and mixed, the solution is adjusted to a concentration of 4.5-7.5% by the active Dibornol-HEC substance with saline (water for injection) and centrifuged, if necessary, the solution is filtered, the resulting drug solution is poured into glass vials or ampoules, which are sealed and packaged.EFFECT: pharmaceutical injection form of the invention is stable.2 cl, 1 tbl, 15 ex

etalloporphyrin treatment of neurological diseases // 2623207
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to neurology and toxicology, and concerns treatment of neurological diseases using metalloporphyrins. For this purpose, an effective amount of AEOL10150 compound is introduced.EFFECT: reduced brain damage when exposed to chemical toxic agents by reducing oxidative stress and mitochondrial dysfunction in brain cells.22 cl, 7 ex, 17 dwg, 2 tbl
Device for water hydrogenation // 2620802
FIELD: chemistry.SUBSTANCE: device for water hydrogenation contains a hydrogen generator 3, a tank 4 for the preparation of hydrogen water, a line for water supply and diversion of water to the consumer, shut-off and regulating armature. The container 4 for the preparation of hydrogenated water contains a hydrogenation catalyst and is connected through a non-return valve to the hydrogen generation unit. The hydrogen generation unit consists of a hydrogen generator 3 connected 6 to the means of maintaining hydrogen pressure and shutting off the hydrogen generator 3 when the hydrogen pressure is exceeded, and the tank 2 with desalted water. The tank 2 with desalted water is connected to the hydrogen generator 3 by a line for supplying desalted water and hydrogen supply to it.EFFECT: invention allows to remove all oxidants from water, ensure saturation of water with hydrogen and create in it a negative oxidation-reduction potential in the absence of the possibility of creating in the water genotoxic activity.2 cl, 2 dwg

Complex forming compounds // 2619939
FIELD: pharmacology.SUBSTANCE: new formula (I) compounds are prepared, as well as their complexes, which can be used to prepare a pharmaceutical composition for prevention and treatment of strontium, tin or lead poisoning.EFFECT: increased application effeciency.13 cl, 9 tbl, 18 ex, 13 dwg
ethod for oxidative stress correction under conditions of ultraviolet irradiation // 2619875
FIELD: medicine.SUBSTANCE: laboratory rats receive daily oral administration of the herb infusion of corn grassworm at a rate of 5 ml/kg of mass 20 minutes before exposure to ultraviolet rays, under ultraviolet irradiation conditions. The infusion is obtained by infusion of 5 g of herbs for 200 ml of boiling water for 60 minutes.EFFECT: method provides oxidative stress correction based on reduced content of lipid peroxidation products in irradiated rats and increased activity of antioxidant system with a shortened phytocorrection course.3 tbl
ethod for preparing agent having stressprotective and antioxidant activity // 2619856
FIELD: pharmacology.SUBSTANCE: cornflower saw-wort grass, crushed to the size of 1.0-2.0 mm, is extracted three times at 60°C at the ratio of raw materials in pts. wt. and the extractant in pts.vol. 1:12. The first phase contact - 70%-ethyl alcohol for 90 minutes, the second phase contact - 40%-ethyl alcohol for 60 minutes and the third phase contact - 20%-ethyl alcohol for 60 minutes. The combined aqueous alcohol extracts are filtered, evaporated, purified by separation, residual evaporated, then dried in a vacuum drying apparatus.EFFECT: method allows to expand the range of herbal medicines with stressprotective and antioxidant activity.15 tbl, 1 ex

edication for prevention and treatment of free radical pathology in animals // 2619342
FIELD: veterinary medicine.SUBSTANCE: medication for the prevention and treatment of Pathology findings in animals contains 3.0-5.0 mas.% of phenyl-tert-butilnitrona, 1.0-2.0 mas.% β-carotene, 7.5-10.5 mas.% 2.6-ditretbutil-4-nonylphenol, 10.0-15.0 mas.% of 2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo-(3,3,0)-oktadyselenon-3.7, 5.0-9.0 mas.% Solutol HS15, 0.2-0.4 mas.% Polyvinylpyrrolidone and water for injection (the rest).EFFECT: increasing the stress resistance of the organism, reducing toxicity and increased ease of use and dosage.dwg 6 7 ex
ethod for organism adaptability increasing under uv exposure // 2616504
FIELD: medicine.SUBSTANCE: drug is administered to laboratory animals daily, 20 minutes before exposure to ultraviolet rays. At that, rats receive 500 mg/kg of arabinogalactan intramuscularly for 6 days, as a drug.EFFECT: increased adaptation capabilities of organism in terms of ultraviolet radiation, based on the reduction of radical products and lipid peroxides content in bodies of irradiated rats and increase of antioxidant activity, under the conditions of reduced duration of the correction course (to 6 days) compared to the prototype.3 tbl

edication for prevention and treatment of mycotoxicoses of small ruminants // 2614996
FIELD: agriculture.SUBSTANCE: medication comprises humic acids, fine silica, selenium taken of small-size condition and zero valency, fat-soluble vitamin E, and distilled water. The components are taken in a specific ratio.EFFECT: use of the invention enables to prevent and treat gastrointestinal diseases of animals, including those related to mycotoxins.2 tbl, 4 ex
3-methyl-1,2,4-triazole-5-thioacetate (s) -2,6-diaminohexane acid application as active drug base for prevention and treatment of cns vital functions in case of severe forms of acute ethanol poisoning // 2613875
FIELD: pharmacy.SUBSTANCE: 3-methyl-1,2,4-triazole-5-thioacetate (s)-2,6-diaminohexane acid application as active drug base for prevention and treatment of cns vital functions in case of severe forms of acute ethanol poisoning is proposed.EFFECT: highly effective prevention of central nervous system vital functions in case of preventive administration, adjustment of neurotoxic lesions in case of severe forms of acute ethanol poisoning, which in turn allows earlier restoration of the central nervous system vital functions and mortality reduction in case of acute ethanol poisoning.1 tbl
ixture of medicinal plants with antioxidant activity // 2613171
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to mixture of medicinal plants with antioxidant activity. Mixture of medicinal plants with antioxidant activity includes shoots of Atragene sibirica, green leaves of Bergenia crassifolia and herb of meadowsweet, in specified ratio of components.EFFECT: mixture possesses increased antioxidant action.1 tbl, 5 ex
ethod of increasing radioresistance in small cattle, subjected to ionizing radiation // 2613102
FIELD: medicine; veterinary science; physics.SUBSTANCE: invention relates to radiation biology and radiation medicine and is intended for prevention and treating acute radiation disease caused by ionizing radiation. Method involves using preparation curcumine in amount of 3.125–3.47 mg of pure substance of curcumine per 1 kg of live weight, injected intramuscularly in dose of 10.0 cm3 0.5–1.0 h after irradiation, if absorbed dose is 4.0–5.0 Gy, and intramuscularly in dose of 10.0 cm3 0.5–1.0 h after irradiation and additionally in dose of 10.0 cm3 on 3 and 5 days after irradiation, if absorbed dose is 5.0–6.0 Gy.EFFECT: method is highly effective for increasing radioresistance in small cattle, subjected to ionizing radiation.1 cl, 2 tbl, 1 ex

Enterosorbent for directed sorption of cholera exotoxin, dosage form of enterosorbent for directed sorption of cholera exotoxin // 2611356
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, particularly, to production of the enterosorbent for directed sorption cholera exotoxin. Enterosorbent for directed sorption cholera Exotoxin, obtained by immobilization by method of adsorption antitoxic anticholeraic immunoglobulin G, recovered from blood serum of animals immunized with cholera toxin, on microparticle size 200–300 nm of pre-treated acid-soluble chitosan in ratio of 0.08–0.1:1. Solid dosage form of enterosorbent for directed sorption cholera exotoxin.EFFECT: above solution enables to obtain a medicinal agent for directed sorption of cholera exotoxin and ensure reduction or complete neutralization of action of cholera exotoxin.5 cl, 5 tbl, 6 ex

Agent increasing expression of redox factors // 2606856
FIELD: medicine.SUBSTANCE: present invention provides maintenance of homeostasis of organisms and concerns: agent for reducing expression IL-1β in the skin of object and for increasing of expression of redox associated factor in human epidermal cell. Agent can include kaempferol, where redox factor is selected from group, consisting of one or more of the number of thioredoxin, thioredoxin reductase, glutathione reductase and glutaredoxin. Agent can include extract of ginkgo leaves, obtained by dissolving 50 % ethanol extract of Ginkgo biloba L. leaves in 1,3-butyleneglycol, where redox-associated factor is thioredoxin and/or thioredoxin reductase. Agent can include extract of galanga Kaempferia galanga, prepared by extraction with 50 % 1,3-butyleneglycol, where redox-associated factor is selected from group consisting of one or more of the number of thioredoxin, thioredoxin reductase, glutathione reductase and glutaredoxin.EFFECT: maintenance of homeostasis of organisms.16 cl, 6 ex, 6 dwg

Novel compound with effects of thrombolysis, accepting free radicals and directed action on thrombus, as well as method for production and use thereof // 2604193
FIELD: chemistry.SUBSTANCE: invention relates to a novel compound of formula I-1, characterised by effects of thrombolysis, accepting free radicals and directed action on thrombus. Compound is a three-component conjugate formed by conjugation of thrombolytic oligopeptide, free radical acceptor and a peptide with directed action on thromb/antithrombotic oligopeptide by binder link.EFFECT: present invention also relates to a pharmaceutical composition containing compounds, wherein compounds form a nanospherical structure.13 cl, 40 dwg, 21 tbl, 17 ex

ethod for producing agent possessing anti-ischemic and antioxidant activity // 2603465
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, particularly to a method for producing the agent, possessing anti-ischemic and antioxidant activity. Disclosed is a method for producing agent possessing anti-ischemic and antioxidant activity, by grinding plant repertory, comprising Membranous Milk Vetch roots, Baikal skullcap roots, Siberian Alexandrian laurel rhizomes and roots, by its three-stage extraction with 60 % ethanol, then, banded aqueous-alcoholic extracts are being filtered, evaporated, purified by separation, finally boiled out, then dried in a vacuum drying apparatus under certain conditions.EFFECT: agent produced as described above possesses the evident anti-ischemic and antioxidant activity.1 cl, 10 tbl

ethod of producing water-soluble lyophilisate of 4-(3-oxo-3-ethoxypropanoyl)amino)benzoic acid possessing anti-ischemic and antioxidant activity // 2602665
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a method of producing a water-soluble lyophilisate, involving producing a combined solution of an active substance and a compound containing hydroxyl and amino groups (amino alcohol), characterized by that the active substance is 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid (EPABA) possessing anti-ischemic and antioxidant activity. Amino alcohol is selected from a group of N-methylglucamine or tris(hydroxymethyl)aminomethane; herewith the said substance and amino alcohol taken in the molar ratio from 1:1 to 1:10 are dissolved in water, the solution is added with an acid agent up to pH 6.8-7.5, neutral solution is filtered, frozen and dried by sublimation.EFFECT: invention enables to obtain water-soluble stable neutral lyophilisates of EPABA corresponding to process requirements of preparations for parenteral administration.3 cl, 4 dwg, 4 tbl, 2 ex
Agent possessing general strengthening and antioxidant action // 2601624
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent possessing general tonic, antioxidant action. Agent contains apple pectin, source of biologically active substances (BAS), glutathione, amino acids, potassium sorbate, water with negative oxidation-reduction potential from -200 to -240 mV, taken in a certain amount. BAS source is selected from: extract of red wine, and/or extract of hawthorn fruits, and/or cranberry fruit extract, and/or rosehips extract with vitamin C, and/or extract of spinach, and/or extract of stems and pineapple fruits, and/or celery extract, and/or red bilberry extract, and/or extract of juniper, and/or melon extract, and/or orange extract, and/or oat extract, and/or extract of black currants, and/or sprouts extract broccoli, and/or ginger root extract, and/or mango extract, and/or walnut extract, and/or extract of berries, and/or extract of green tea, and/or Bilberry fruit extract, and/or raspberry extract and/or quercetin, and/or soya isoflavones. Amino acid selected from: alanine, and/or aspartic acid, and/or glutamine, and/or glutamic acid, and/or arginine, and/or leucine, and/or lysine, and/or proline.EFFECT: agent described above possesses the pronounced general tonic, antioxidant action, increased storage life.4 cl, 9 ex

Agent for prevention of acute radiation disease // 2599844
FIELD: medicine.SUBSTANCE: invention refers to medical radiology and can be used for prevention of acute radiation disease caused by external radiation. Proposed is the use as an agent for prevention of acute radiation disease of tizanidine-5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazol hydrochloride in the form of legal drugs "Tizanidine Teva", "Sirdalud" and "Tizalud". Previously these preparations based on tizanidine used in medicine as antispastic agents to reduce spasticity and convulsive reaction of skeletal muscles of various aetiologies.EFFECT: technical result is ensuring radiation protection in conditions of total short-term gamma radiation in doses of about CD90/30 comparable with the efficiency of the prototype means (cystamine), in reduction in 50-100 times the effective dose of a radioprotector and in faster development of the radiation-proof effect 4-6 times.1 cl, 2 tbl, 2 ex

ethod of producing coordination compounds of oligogalacturonic acid with biogenic metals (ii) as delivery systems of biogenic metals (ii) and systems for removing heavy metals (ii) // 2599494
FIELD: medicine.SUBSTANCE: invention relates to pharmacology, and describes a method of producing coordination compounds of oligogalacturonic acid with biogenic metals (II). Method involves production of pectin-containing preparation of oligogalacturonic acid with polymerisation degree equal to no less than 10, subjected to reaction with metal salt (II): copper, cobalt, iron, zinc, manganese, magnesium in aqueous medium at neutral pH, exposing reaction mixture at room temperature, neutralisation of formed acid, water flushing, centrifugation and drying precipitate. According to invention to 1 l of 5.0·10-3 M aqueous solution of purified oligogalacturonic acid while stirring is added first 2 M aqueous solution of ammonia hydrate to pH 8, then 1 l of 4.5·10-2 M aqueous solution of metal acetate (II); formed gel-like precipitate is treated with 96 % ethanol at volume ratio of 1:2, held for 2 hours.EFFECT: invention ensures delivery of biogenic metals (II), as well as removal of heavy metal cations (II) from body.1 cl, 8 tbl, 4 dwg, 6 ex
Fodder additive for farm animals with enteric coating containing sodium metabisulphite for detoxification of vomitoxin // 2598722
FIELD: agriculture.SUBSTANCE: group of inventions relates to a fodder additive and a fodder product for farm animals, in which the particle-nucleus containing sodium metabisulphite and at least one binder has an enteric coating, herewith the thickness and the coating composition protect the sodium metabisulphite from decomposition to sulphur dioxide in an acidic aqueous medium of the stomach.EFFECT: group of inventions provides delivery of sodium metabisulphite into the lower segments of the gastrointestinal tract as an antidote in case of swallowed vomitoxin by animals.13 cl, 5 ex, 4 tbl

Agent having antioxidant, anti-tumor, immunomodulatory, anti-diabetic and anti-bacterial action // 2598349
FIELD: medicine.SUBSTANCE: proposed agent having antioxidant, anti-tumor, immunomodulatory, anti-diabetic and anti-bacterial action, relates to medicine. It comprises an aqueous extract from plant material. As a raw material use peach and birch leaves. In addition, agent contains ascorbic acid and the trivalent chromium microelement in the amounts indicated in the invention formula.EFFECT: agent of the invention expands the range of drugs, has no adverse side effects and can be recommended for long-term continuous use.1 cl, 1 dwg, 4 tbl

ethod of treating and preventing dysmetabolic nephropathy in children associated with toxic action of cadmium, lead, chrome and phenol of anthropogenic origin // 2598346
FIELD: medicine.SUBSTANCE: invention relates to medicine, and is intended for treatment and prevention of toxic dysmetabolic nephropathy in children living in the zone of influence of industrial enterprises under the conditions of the atmospheric air contamination with cadmium, lead, chromium and phenol. Treatment is carried out in two stages. First stage involves combined application by children: polyvitamins with micro-and macro-elements of the "Vitrum" series orally within the course of 21 day 1 tablet once a day after meal: "Vitrum-baby" - children 3-4 years old; "Vitrum-kids" - children 4-7 years old; "Vitrum-junior" - children older than 7 years, and the "Elcar" product orally within the course of 10 days in an age dosage for children aged 3-6 years old - with a single dose of 0.1 g-5 drops 2-3 times a day or with a daily dose of 0.2-0.3 g - 11-16 drops; with an age dosage in children aged over 6 years old - with a single dose of 0.2-0.3 g - 11-16 drops 2-3 times a day or with a daily dose of 0.4-0.9 g - 22-48 drops. At the second stage, after the "Elcar" course termination, "Xydiphone" is added to the treatment regimen in therapeutic doses within the course of 10 days for children aged 3-10 years old - 1 dessert spoon 2-3 times a day; and for children older than 10 years - 1 table spoon 2-3 times a day.EFFECT: method provides higher treatment effectiveness.3 cl, 5 tbl

ultifunctional nitroxide derivatives and uses thereof // 2597265
FIELD: pharmaceutics.SUBSTANCE: invention provides multifunctional nitric oxide derivatives of formula I: I, where Y is N, CH or N(→O), or its enantiomer, diastereomers, racemic mixture or its pharmaceutically acceptable salt or solvate, where A is a fragment of general formula II connected through its terminal -NH group with any atom of carbon of pyridine, phenyl or pyridine-oxide ring: II; X is absent or is -(CR2R2)n-; R1 is absent or is represented by from 1 to 5 substituents, each of which is independently selected from a halogen, -CN, -OH, -NO2, -N(R6)2, -OCF3, -CF3, -OR6, -COR6, -COOR6, -CON(R6)2, -OCOOR6, -OCON(R6)2, -(C1-C8)alkyl, -(C1-C8)alkylen-COOR6, -SR6, -SO2R6, -SO2N(R6)2 or -S(=O)R6; R2 is H; R3 each independently represents a (C1-C8)alkyl; R4 is selected from H or -(C1-C8)alkyl; R5 is selected from H or -CN; R6 each is independently selected from H or (C1-C8)alkyl and n is an integer equal to 1 or 2.EFFECT: said compounds contain a potassium channels opener and a catalyst for degradation of reactive forms of oxygen (RFO), which can act as an antioxidant; also proposed are pharmaceutical compositions containing the said compounds, which can be used for treating diseases, disorders or conditions related to oxidative stress or endothelial dysfunction.19 cl, 9 dwg, 5 tbl, 14 ex

Therapeutic agent, sensitive to metal-salen complex compound, and system for regulation of intracorporeal properties for metal-salen complex compound // 2595840
FIELD: pharmaceutics.SUBSTANCE: described is therapeutic agent for treating tumours. Device contains magnetic complex compound “Fe-Salen” as medicinal component, as well as chelating agent. Said agent is used for chelating metal complex compound “Fe-Salen” as sensitive component for suppression of side effects of “Fe-Salen” complex compound. Complex compound “Fe-Salen” is localized in affected area due to action of external magnetic field on body, and after exposure to external magnetic field chelating agent is bound with complex compound “Fe-Salen”, which is released from affected region of body. Chelating agent is either deferasirox or deferoxamine.EFFECT: use in invention of said chelating agents provides suppression of side effects of “Fe-Salen” complex compound.4 cl, 2 ex, 2 dwg

Antioxidant composition (versions) // 2593587
FIELD: pharmaceutics. SUBSTANCE: invention relates to pharmaceutical industry and represents use of antibacterial and antiviral pharmaceutical composition, having pronounced anticancer, antibacterial and antioxidant properties, containing silver nitrate, hexamethylenetetramine, sodium thiosulphate, alpha-aspartic acid or asparagine, nicotinic acid and water, wherein ingredients of composition are taken in a certain ratio, wt%, and also represents use of antibacterial and antiviral pharmaceutical composition, having pronounced anticancer, antibacterial and antioxidant properties, containing silver nitrate, hexamethylenetetramine or imidazole, alpha-aspartic acid or asparagine, nicotinic acid, imidazole-containing compounds of platinum cis-[Pt (NH3)2Im2]Cl2 or CIS-[Pt (NH2OH)2Im2]Cl2 and water, wherein ingredients of composition are taken in certain ratio, wt%. EFFECT: invention widens range of agents for said purpose, wherein claimed composition can be used as an integral part or as independent preparation, having therapeutic and preventive properties, preventing damage to cells by free radicals, improving body defences and promoting tissue regeneration. 2 cl, 2 ex, 1 tbl

Antioxidant composition // 2593010
FIELD: medicine; pharmaceuticals. SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents an antioxidant composition containing lithium aspartate in amount of 40-60 wt% and lithium succinate in amount of 40-60 wt%. Disclosed composition allows for long-term storage and retains activity at room temperature for six months. EFFECT: invention provides a wider range of antioxidant agents. 1 cl, 1 tbl, 3 ex

Composition for body detoxification // 2591791
FIELD: biotechnology; food industry.SUBSTANCE: invention relates to production of functional food products for normalisation of body status and biologically active supplements (BAS) and medicinal preparations for normalisation of digestive tract condition (removal of toxic substances). Composition for cleaning the organism from toxins in the form of a gel contains, as active components, an insoluble enterosorbent and soluble enterosorbent forming a matrix-like base for the insoluble sorbent, as well as additives for preparing a product of the required consistency.EFFECT: composition effectively binds and retains within the matrix connected toxins, provides effective detoxifying effect when using a significantly less amount of product, while reducing undesirable side effects associated with use of detoxication agents.10 cl, 7 tbl

ethod for prevention of stress in chickens for meat production at beak trimming // 2588542
FIELD: veterinary science.SUBSTANCE: invention relates to a method for prevention of stress in chickens for meat productivity during beak trimming. Method involves using pharmacological agents possessing antistress action. Chickens from birth and up to 7-10-days of age take water with a daily dose of 280-320 mg/kg of body weight of a pharmacological complex containing following components, wt%: betaine 30-35; ascorbic acid 10-15; succinic acid 10-15; L-carnitine tartrate 15-20; butaphosphane 8-10; glucose - balance. Additionally 2-3 days prior to beak trimming, on beak trimming day and 2-3 days after beak trimming in a dose of 230-250 mg/kg of body weight is used pharmacological complex including, wt%: lithium citrate 8-10; ascorbic acid 10-15; succinic acid 10-15; butaphosphane 30-35; L-carnitine tartrate 15-20; glucose - balance, and 2-3 days prior to beak trimming, on beak trimming day and 1-2 days after beak trimming daily fodder is taken with vitamin K in a dose of 50-100 mg per chicken.EFFECT: invention allows effective prevention of stress, reduces chicken waste, increases average daily weight gain.1 cl, 8 tbl

ethod for preparation of liquid antioxidant // 2587541
FIELD: chemistry.SUBSTANCE: invention relates to method of liquid antioxidant preparing. Method consists in fact that in fresh water in vessel in equilibrium with environment, potato starch is filled at a weight ratio of starch to water of 1:(50-100), then liquid is mixed and left in vessel for 16-24 hours, during this period contents of vessel is stirred 4-8 times. Before filling in starch, water is boiled and cooled to room temperature.EFFECT: ease of producing liquid antioxidant and low price of its main component, potato starch.1 cl, 2 dwg

Bis- (3- (3,5-di-tert-butyl-4-hydroxyphenyl) propyl) selenide, having antioxidant and hypoglycemic activity // 2586067
FIELD: chemistry.SUBSTANCE: invention relates to selenium-containing phenol compound - bis-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl)selenide with formula: .EFFECT: disclosed compound exhibits high antioxidant activity, low toxicity and hypoglycaemic action with underlying diabetes, and can be used in medicine, veterinary and experimental biology.1 cl, 1 dwg, 3 tbl, 5 ex

Agent with liposomes containing nicotinic acid and propolis extract having detoxification and antioxidant activity // 2585099
FIELD: chemistry.SUBSTANCE: invention relates to an agent possessing detoxification and antioxidant activity. Agent contains nicotinic acid and 10% alcohol extract of propolis, included in liposomes. Said liposomes are obtained by mixing at 40°C egg lecithin and cholesterol, taken in ratio 1:0.2, followed by hydrating with solution of sucrose. Liposomes are enclosed in capsules for oral administration in following ratio of components of liposomes per 1 capsule: 0.2 g nicotinic acid, 0.2 g of 10 % alcohol extract of propolis, 0.22 g of mixture of lecithin and cholesterol 1:0.2, hydrated with 0.5 % sucrose solution.EFFECT: invention is characterised by high bioavailability and marked prolonged action, providing maximum delivery of active substances of gastrointestinal tract in blood flow.3 cl, 5 tbl, 7 ex

Antidote for carbon monoxide and hepatotoxic substances // 2584586
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pharmacology, and describes antidote of carbon monoxide and hepatotoxic substances. Antidote is ammonia-zinc salt of soluble oxidised lignin with general formula (CxHyOz)n(NH3)k(Zn)m, where x = 14-16; y = 11-13; z = 5-7; n = 1.0-20; k = 1-30; m = 1-1.2.EFFECT: higher efficiency of treatment and prevention of poisoning with carbon monoxide (CO) and hepatotoxic agents and can be used for treating hypoxic states of various aetiology.1 cl, 7 ex, 11 tbl

Agent for reducing mutagenic action of lead acetate in body // 2584347
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent for reducing mutagenic action of lead acetate in a body. Agent for reducing mutagenic action of lead acetate in body, representing 0.7 % decoction of ragwort leaves and roots or alcoholic tincture of ragwort flower, produced by infusion of fresh flower hands, in budding stage, 40 % ethanol in ratio 1:5.EFFECT: agent described above is effective for reducing mutagenic action of lead acetate in body.1 cl, 1 tbl, 1 ex
 
2551054.
Up!